Trial results

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504 on ClinicalTrials.gov · last registry update 2026-08-04

Registered but not yet open, with 285 participants planned. Due to report 18 May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Relative change in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

285

Started

2026-08-04

Primary completion

2027-05-18 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative change in body weight

Conditions studied

Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.